{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:14:05Z","timestamp":1793258045983,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jacc.2025.12.015","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:22:32Z","timestamp":1770218552000},"page":"2006-2033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["MASLD, MASH, and the CKM Spectrum"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven M.","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-2057","authenticated-orcid":false,"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Eve","family":"Pich\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-4569","authenticated-orcid":false,"given":"Harriette G.C.","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.12.015_bib1","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.37765\/ajmc.2024.89670","article-title":"An overview of cardiovascular-kidney-metabolic syndrome","volume":"30","author":"Ferdinand","year":"2024","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jacc.2025.12.015_bib2","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.12.015_bib3","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.12.015_bib4","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.12.015_bib5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib6","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1161\/CIRCULATIONAHA.120.046783","article-title":"Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary prevention settings","volume":"142","author":"Wright","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.12.015_bib7","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in us adults, 2011-2020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.12.015_bib8","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.12.015_bib9","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction\u2013associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib10","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","article-title":"Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction\u2013associated steatotic liver disease (MASLD) and metabolic dysfunction\u2013associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jacc.2025.12.015_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.036","article-title":"Exclusion of liver disease and underutilization of liver-specific endpoints in heart failure trials","volume":"13","author":"Khan","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.12.015_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.14309\/ajg.0000000000003215","article-title":"A pragmatic management approach for metabolic dysfunction\u2013associated steatosis and steatohepatitis","volume":"120","author":"Shah","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jacc.2025.12.015_bib14","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCRESAHA.125.325602","article-title":"Cardiovascular, kidney, liver, and metabolic interactions in heart failure: breaking down silos","volume":"136","author":"Lee","year":"2025","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.12.015_bib15","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1681\/ASN.0000000752","article-title":"Rapid and simultaneous initiation of guideline-directed kidney therapies in patients with CKD and type 2 diabetes","volume":"36","author":"Rashid","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.12.015_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.jacc.2025.12.015_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.ackd.2021.04.005","article-title":"Kidney outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes","volume":"28","author":"Mosenzon","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.jacc.2025.12.015_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1573399813666170414101450","article-title":"Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: a meta-analysis","volume":"14","author":"Peterson","year":"2018","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.jacc.2025.12.015_bib20","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction\u2013associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2024.05.005","article-title":"Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: a trial-level analysis","volume":"84","author":"Ostrominski","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102344","article-title":"Cardiovascular-kidney-metabolic (ckm) syndrome: a state-of-the-art review","volume":"49","author":"Sebastian","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jacasi.2025.04.007","article-title":"Prevalence and mortality of cardiovascular-kidney-metabolic syndrome in china: a nationwide population-based study","volume":"5","author":"Zheng","year":"2025","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacc.2025.12.015_bib24","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Nonalcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jacc.2025.12.015_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13992","article-title":"Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease","volume":"39","author":"Paik","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2025.12.015_bib26","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/nu16071015","article-title":"Visceral adipose tissue: the hidden culprit for type 2 diabetes","volume":"16","author":"Dhokte","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2025.12.015_bib27","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib28","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1172\/JCI137050","article-title":"Insulin-stimulated lipogenesis gets an epigenetic makeover","volume":"130","author":"Manuel","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2025.12.015_bib29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2025.12.015_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf260","article-title":"The impact of metabolic dysfunction\u2013associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management","volume":"18","author":"Moncho","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jacc.2025.12.015_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab"},{"key":"10.1016\/j.jacc.2025.12.015_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fcvm.2020.00022","article-title":"Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease","volume":"7","author":"Chait","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease and the heart","volume":"82","author":"Driessen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.12.015_bib34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jacc.2025.12.015_bib35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1053\/j.gastro.2025.03.010","article-title":"Regulation of hepatic stellate cell phenotypes in metabolic dysfunction\u2013associated steatohepatitis","volume":"169","author":"Kisseleva","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.12.015_bib37","article-title":"Nonalcoholic fatty liver disease (NAFLD) and its association to cardiovascular disease: a comprehensive meta-analysis","volume":"14","author":"Mladenova","year":"2025","journal-title":"JRSM Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2025.12.015_bib38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12882-024-03910-6","article-title":"Does metabolic dysfunction\u2013associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies","volume":"25","author":"Liu","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jacc.2025.12.015_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70104","article-title":"Association of liver fibrosis scores with all-cause and cardiovascular mortality in patients with heart failure","volume":"17","author":"Guo","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jacc.2025.12.015_bib40","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.12.015_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112418","article-title":"Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction\u2013associated steatotic liver disease and liver fibrosis assessed by transient elastography: a cross-sectional study based on NHANES 2017-2020","volume":"227","author":"Xu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2025.12.015_bib42","article-title":"Metabolic syndrome\u2013related kidney injury: a review and update","volume":"13","author":"Lin","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.12.015_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1531295","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes","volume":"16","author":"Colletta","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.12.015_bib44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2174\/1573403X15666190730094215","article-title":"SGLT2 inhibitors and cardiovascular outcomes: do they differ or there is a class effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL study","volume":"16","author":"Kyriakos","year":"2020","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.jacc.2025.12.015_bib45","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing sglt2 inhibitors in patients with ckd: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jacc.2025.12.015_bib46","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in nonalcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2025.12.015_bib47","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41591-024-03223-z","article-title":"Integrating liver endpoints in clinical trials of cardiovascular and kidney disease","volume":"30","author":"Zannad","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.13793","article-title":"MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials","volume":"296","author":"Zannad","year":"2024","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021654","article-title":"Nonalcoholic fatty liver disease and risk of heart failure among medicare beneficiaries","volume":"10","author":"Fudim","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.12.015_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jchf.2018.10.007","article-title":"Heart failure and liver disease: cardiohepatic interactions","volume":"7","author":"Xanthopoulos","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.12.015_bib51","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials in high-impact general medical journals: a systematic sampling review","volume":"297","author":"Van Spall","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.12.015_bib52","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.15420\/ecr.2021.33","article-title":"Management of heart failure in patients with chronic kidney disease","volume":"17","author":"Ryan","year":"2022","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of nonalcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib54","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.12.015_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299507","article-title":"Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis","volume":"19","author":"Gurun","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.12.015_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108226","article-title":"Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus","volume":"36","author":"Mikolasevic","year":"2022","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jacc.2025.12.015_bib57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib58","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/dom.14978","article-title":"Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: a post hoc analysis of the CREDENCE trial","volume":"25","author":"Koshino","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.12.015_bib59","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib61","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib62","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2024.12.006","article-title":"Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Xiang","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib63","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib64","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133174","article-title":"The prognostic role of Fibrosis-4 score in heart failure with reduced ejection fraction","volume":"429","author":"Mohamed","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib66","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0031-1284434","article-title":"Liver abnormalities in cardiac diseases and heart failure","volume":"20","author":"Alvarez","year":"2011","journal-title":"Int J Angiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib67","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction\u2013associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib68","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jacc.2025.12.015_bib69","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/ejhf.3722","article-title":"Liver stiffness measurement for noninvasive assessment of central venous pressure in patients with heart failure: a multicentre pilot study","volume":"27","author":"Girerd","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.12.015_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70280","article-title":"Real-world assessment of liver corrected T1 and magnetic resonance elastography in predicting liver disease progression","volume":"45","author":"Corey","year":"2025","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.jacc.2025.12.015_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1012289","article-title":"Credibility assessment of in silico clinical trials for medical devices","volume":"20","author":"Pathmanathan","year":"2024","journal-title":"PLoS Comput Biol"},{"issue":"11","key":"10.1016\/j.jacc.2025.12.015_bib73","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jacc.2025.12.015_bib75","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1007\/s00330-020-06858-x","article-title":"Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C)","volume":"30","author":"Mamidipalli","year":"2020","journal-title":"Eur Radiol"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2025.12.015_bib76","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/db24-248-OR","article-title":"Pro\u2013B-type natriuretic peptide strongly predicts major cardiovascular events and cardiovascular mortality in cardiovascular disease patients with NAFLD as well as in those without NAFLD [abstract]","volume":"73","author":"Plattner","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.12.015_bib77","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.3390\/jcm14082690","article-title":"Effect of metabolic dysfunction\u2013associated steatotic liver disease (MASLD) on left ventricular mechanics in patients without overt cardiac disease: a systematic review and meta-analysis","volume":"14","author":"Sonaglioni","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib78","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4093\/dmj.2020.0118","article-title":"Albuminuria is associated with steatosis burden in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"45","author":"Han","year":"2021","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jacc.2025.12.015_bib79","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.2337\/dc24-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.12.015_bib80","first-page":"2180","article-title":"Rethinking composite endpoints with the win ratio: a breakthrough or business as usual?","volume":"40","author":"Grubic","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2013.09.002","article-title":"Multiparametric magnetic resonance for the noninvasive diagnosis of liver disease","volume":"60","author":"Banerjee","year":"2014","journal-title":"J. Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib82","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2337\/db23-0926","article-title":"Quantitative imaging reveals steatosis and fibroinflammation in multiple organs in people with type 2 diabetes: a real-world study","volume":"73","author":"Diamond","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.12.015_bib83","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.drudis.2018.01.045","article-title":"Opportunities and pitfalls in clinical proof-of-concept: principles and examples","volume":"23","author":"Chen","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jacc.2025.12.015_bib84","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3390\/ph16111540","article-title":"Radiotracers for imaging of fibrosis: advances during the last two decades and future directions","volume":"16","author":"Eriksson","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jacc.2025.12.015_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.107912","article-title":"Association of glycemia with insulin sensitivity and \u03b2-cell function in adults with early type 2 diabetes on metformin alone","volume":"35","author":"Utzschneider","year":"2021","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jacc.2025.12.015_bib86","series-title":"Physiology, renin angiotensin system. StatPearls","author":"Fountain","year":"2025"},{"key":"10.1016\/j.jacc.2025.12.015_bib87","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000223","article-title":"NIS2+, an effective blood-based test for the diagnosis of at-risk nonalcoholic steatohepatitis in adults 65 years and older","volume":"7","author":"Sanyal","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jacc.2025.12.015_bib88","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1007\/s10620-021-07277-8","article-title":"Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography","volume":"67","author":"Podrug","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jacc.2025.12.015_bib89","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fphys.2019.01028","article-title":"Baveno criteria safely identify patients with compensated advanced chronic liver disease who can avoid variceal screening endoscopy: a diagnostic test accuracy meta-analysis","volume":"10","author":"Szak\u00e1cs","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib90","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1053\/j.gastro.2016.10.010","article-title":"Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage?","volume":"151","author":"Chalasani","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.12.015_bib91","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v17.i5.105072","article-title":"Open questions on how metabolic dysfunction\u2013associated steatotic liver disease shapes the course of drug-induced liver injury","volume":"17","author":"Ram\u00edrez-Mej\u00eda","year":"2025","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100666","article-title":"Association of index and changes in fibrosis-4 score with outcomes in metabolic dysfunction\u2013associated steatohepatitis","volume":"4","author":"Gbadamosi","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.jacc.2025.12.015_bib93","doi-asserted-by":"crossref","first-page":"ehae666","DOI":"10.1093\/eurheartj\/ehae666.1168","article-title":"An Elevated FIB-4 score is associated with the severity of heart failure","volume":"45","author":"Bielecka-Dabrowa","year":"2024","journal-title":"European Heart Journal"},{"key":"10.1016\/j.jacc.2025.12.015_bib94","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10741-011-9261-3","article-title":"Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome","volume":"17","author":"Colombo","year":"2012","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2025.12.015_bib95","doi-asserted-by":"crossref","DOI":"10.1159\/000546489","article-title":"Utility of cardiac biomarkers (NT-proBNP and hs-troponin-T) in predicting mortality, cardiovascular and renal outcomes in patients with chronic kidney disease","author":"Vasan","year":"2025","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2025.12.015_bib96","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2337\/dc20-1889","article-title":"Insulin-like growth factor binding protein 7 predicts renal and cardiovascular outcomes in the canagliflozin cardiovascular assessment study","volume":"44","author":"Januzzi","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.12.015_bib97","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12933-025-02779-5","article-title":"A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease","volume":"24","author":"Januzzi","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.12.015_bib98","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1515\/cclm-2021-0377","article-title":"Pre-analytical considerations in biomarker research: focus on cardiovascular disease","volume":"59","author":"Revuelta-L\u00f3pez","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib101","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib102","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib103","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/poh2.47","article-title":"Hepatic venous pressure gradient measurement guiding nonselective beta-blocker therapy in a patient with clinically significant portal hypertension","volume":"2","author":"Wang","year":"2023","journal-title":"Port Hypertens Cirrhos"},{"key":"10.1016\/j.jacc.2025.12.015_bib104","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of noninvasive tests and histology for the prediction of clinical outcomes in patients with nonalcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib105","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/liv.15561","article-title":"High accuracy of spleen stiffness measurement in diagnosing clinically significant portal hypertension in metabolic-associated fatty liver disease","volume":"43","author":"Odriozola","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2025.12.015_bib106","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1002\/hep4.2091","article-title":"Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: validation of ANTICIPATE models and development of a lab-based model","volume":"6","author":"Rabiee","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jacc.2025.12.015_bib107","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.12.015_bib108","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/s41379-021-00851-5","article-title":"Transient elastography versus liver biopsy: discordance in evaluations for fibrosis and steatosis from a pathology standpoint","volume":"34","author":"Fang","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jacc.2025.12.015_bib109","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2025.12.015_bib110","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol\u2013related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib111","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption\u2014II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"key":"10.1016\/j.jacc.2025.12.015_bib112","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/clc.23773","article-title":"Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: meta-analysis of phase III studies and implications on trial design","volume":"45","author":"Chi","year":"2022","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib113","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.12.015_bib114","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03654-2","article-title":"Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver events","author":"Jackson","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib115","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2024.06.008","article-title":"Liver biopsy evaluation in MASH drug development: think thrice, act wise","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jacc.2025.12.015_bib116","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5152\/dir.2018.17525","article-title":"Predictors of bleeding complications following percutaneous image-guided liver biopsy: a scoping review","volume":"25","author":"Midia","year":"2019","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib117","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1053\/j.gastro.2010.06.015","article-title":"Reduced mortality rates following elective percutaneous liver biopsies","volume":"139","author":"West","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.12.015_bib118","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000423","article-title":"Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction\u2013associated steatohepatitis","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jacc.2025.12.015_bib119","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/13696998.2025.2468582","article-title":"Noninvasive tests and diagnostic pathways to MASH diagnosis in the United States: a retrospective observational study","volume":"28","author":"Gbadamosi","year":"2025","journal-title":"J Med Econ"},{"key":"10.1016\/j.jacc.2025.12.015_bib120","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/HEP.0000000000000618","article-title":"Noninvasive assessment of hepatic decompensation","volume":"81","author":"Thiele","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.12.015_bib122","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejim.2024.01.013","article-title":"Noninvasive testing and risk-stratification in patients with MASLD","volume":"122","author":"Zoncap\u00e8","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib123","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","article-title":"Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis","volume":"162","author":"Loomba","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.12.015_bib125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jceh.2019.09.005","article-title":"Natural history of simple steatosis or nonalcoholic fatty liver","volume":"10","author":"De","year":"2020","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib126","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstr\u00f6m","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib127","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S2468-1253(24)00234-6","article-title":"Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for noninvasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study","volume":"9","author":"Jachs","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib128","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of nonalcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jacc.2025.12.015_bib129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cgh.2025.03.003","article-title":"Change in cT1 following interventions in MASLD: a systematic review and meta-analysis","volume":"24","author":"Andersson","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib130","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.3390\/diagnostics11122341","article-title":"The prevalence of liver steatosis and fibrosis assessed by vibration-controlled transient elastography and controlled attenuation parameter in apparently healthy Romanian medical students","volume":"11","author":"Nastasa","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jacc.2025.12.015_bib131","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jhep.2024.08.031","article-title":"Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH","volume":"82","author":"Alkhouri","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.12.015_bib132","first-page":"9","article-title":"Advances in novel drug therapy for metabolic dysfunction\u2013associated steatohepatitis cirrhosis","volume":"3","author":"Nasir","year":"2025","journal-title":"J Transl Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2025.12.015_bib133","doi-asserted-by":"crossref","first-page":"S630","DOI":"10.1016\/S0168-8278(25)01687-3","article-title":"Baseline characteristics in well-compensated NASH cirrhosis patients diagnosed with or without a liver biopsy in MAESTRO-NASH Outcomes, a clinical outcome phase 3 study assessing the effect of resmetirom in well compensated NASH cirrhosis","volume":"82","author":"Schattenberg","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.12.015_bib136","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1681\/ASN.0000000000000244","article-title":"Validity and utility of a hierarchical composite endpoint for clinical trials of kidney disease progression: a review","volume":"34","author":"Little","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.12.015_bib137","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jacc.2025.12.015_bib138","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13888","article-title":"Desirability of outcome ranking and quality life measurement for antimicrobial research in organ transplantation","volume":"24","author":"Doernberg","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jacc.2025.12.015_bib139","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/cid\/ciad239","article-title":"Exploration of a potential desirability of outcome ranking endpoint for complicated intra-abdominal infections using 9 registrational trials for antibacterial drugs","volume":"77","author":"Kinamon","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jacc.2025.12.015_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jacc.2025.12.015_bib141","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41591-021-01652-8","article-title":"Noninvasive biomarkers of nonalcoholic steatohepatitis: the FNIH NIMBLE project","volume":"28","author":"Sanyal","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.12.015_bib142","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.12.015_bib143","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hep.32594","article-title":"Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD","volume":"77","author":"Gidener","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.12.015_bib144","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12876-017-0609-6","article-title":"The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography","volume":"17","author":"Ratchatasettakul","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jacc.2025.12.015_bib145","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233136","article-title":"Precision and test-retest repeatability of stiffness measurement with mr elastography: a multicenter phantom study","volume":"311","author":"Ozkaya","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.jacc.2025.12.015_bib146","first-page":"14","article-title":"Big data in medicine is driving big changes","volume":"9","author":"Martin-Sanchez","year":"2014","journal-title":"Yearb Med Inform"},{"key":"10.1016\/j.jacc.2025.12.015_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmedinf.2025.105816","article-title":"EHR-ML: a data-driven framework for designing machine learning applications with electronic health records","volume":"196","author":"Ramakrishnaiah","year":"2025","journal-title":"Int J Med Inform"},{"key":"10.1016\/j.jacc.2025.12.015_bib148","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/eurheartj\/ehv164","article-title":"The perils of surrogate endpoints","volume":"36","author":"Weintraub","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.12.015_bib149","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jchf.2019.12.011","article-title":"Endpoints in heart failure drug development: history and future","volume":"8","author":"Fiuzat","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.12.015_bib150","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1478-3231.2009.02100.x","article-title":"Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection","volume":"29","author":"Mederacke","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2025.12.015_bib151","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an endpoint for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2025.12.015_bib155","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/pds.3386","article-title":"Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy","volume":"22","author":"Mack","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2025.12.015_bib156","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70051","article-title":"Twenty-five years of addressing cutting-edge scientific, policy, and regulatory issues through collaboration: the Forum for Collaborative Research","volume":"17","author":"Schaefer","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jacc.2025.12.015_bib157","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and external controls in clinical trials\u2014a primer for researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jacc.2025.12.015_bib159","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.12.015_bib160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0000033","article-title":"A systematic review of federated learning applications for biomedical data","volume":"1","author":"Crowson","year":"2022","journal-title":"PLoS Digit Health"},{"key":"10.1016\/j.jacc.2025.12.015_bib161","article-title":"5 Benefits of docker for the healthcare industry","author":"Singh","year":"2023","journal-title":"Collabnix"},{"key":"10.1016\/j.jacc.2025.12.015_bib163","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2125.2005.02435.x","article-title":"Biomarkers and surrogate endpoints","volume":"59","author":"Aronson","year":"2005","journal-title":"Br J Clin Pharmacol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725104294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725104294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:36:57Z","timestamp":1781253417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725104294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":149,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0735109725104294"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.12.015","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MASLD, MASH, and the CKM Spectrum","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}